Inhibition of SULT2B1b expression alters effects of 3β-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells

Prostate

Volumn 67, Issue 12, 2007, Pages 1318-1329

  He, Dongning ^a   Falany, Charles N ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

5 androstenediol; Androgen receptor; Cell proliferation; Dehydroepiandrosterone; Estrogen receptors; Prostate cancer; Prostate specific antigen (PSA); Short interference RNA (siRNA); Sulfotransferase; SULT2B1b

Indexed keywords

3 BETA HYDROXYSTEROID DERIVATIVE; 3BETA ANDROSTANEDIOL; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTENEDIOL; ESTROGEN; ESTROGEN RECEPTOR; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA; STEROID RECEPTOR; SULFOTRANSFERASE; SULFOTRANSFERASE 2B1B; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SULFATION;

ADENOCARCINOMA; ANDROSTENOLS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, STEROID; RNA, SMALL INTERFERING; SULFOTRANSFERASES; TRANSFECTION;

EID: 34548803011     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20615     Document Type: Article

References (58)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004; 54(1):8-29.
2. Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 2004; 92(4):237-253.
3. Castagnetta L, Granata OM, Cocciadiferro L, Saetta A, Polito L, Bronte G, Rizzo S, Campisi I, Agostara B, Carruba G. Sex steroids, carcinogenesis, and cancer progression. Ann NY Acad Sci 2004;1028:233-246.
4. Soronen P, Laiti M, Torn S, Harkonen P, Patrikainen L, Li Y, Pulkka A, Kurkela R, Herrala A, Kaija H, Isomaa V, Vihko P. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004;92(4):281-286.
5. Chang HC, Miyamoto H, Marwah P, Lardy H, Yeh S, Huang KE, Chang C. Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells. Proc Natl Acad Sci USA 1999; 96(20):11173-11177.
6. Reed MJ, Purohit A, Woo LW, Newman SP, Potter BV. Steroid sulfatase: Molecular biology, regulation, and inhibition. Endocr Rev 2005;26(2):171-202.
7. Berr C, Lafont S, Debuire B, Dartigues JF, Baulieu EE. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: A French community-based study. Proc Natl Acad Sci USA 1996;93(23):13410-13415.
8. Mo Q, Lu SF, Simon NG. Dehydroepiandrosterone and its metabolites: Differential effects on androgen receptor trafficking and transcriptional activity. J Steroid Biochem Mol Biol 2006; 99(1):50-58.
9. Falany CN. Enzymology of human cytosolic sulfotransferases. FASEB J 1997;11(4):206-216.
10. Falany CN, Strom P, Swedmark S. Sulphation of o-desmethylnaproxen and related compounds by human cytosolic sulfotransferases. Br J Clin Pharmacol 2005;60(6):632-640.
11. He D, Falany CN. Characterization of proline-serine-rich carboxyl terminus in human sulfotransferase 2B1b: Immunogenicity, subcellular localization, kinetic properties, and phosphorylation. Drug Metab Dispos 2006;34(10):1749-1755.
12. Meloche CA, Falany CN. Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol 2001;77(4-5):261-269.
13. Falany CN, He D, Dumas N, Frost AR, Falany JL. Human cytosolic sulfotransferase 2 B1: Isoform expression, tissue specificity and subcellular localization. J Steroid Biochem Mol Biol 2006;102(1-5):214-221.
14. Fuda H, Lee YC, Shimizu C, Javitt NB, Strott CA. Mutational analysis of human hydroxysteroid sulfotransferase SULT2B1 isoforms reveals that exon 1B of the SULT2B1 gene produces cholesterol sulfotransferase, whereas exon 1A yields pregnenolone sulfotransferase. J Biol Chem 2002;277(39):36161-36166.
15. He D, Meloche CA, Dumas NA, Frost AR, Falany CN. Different subcellular localization of sulphotransferase 2B1b in human placenta and prostate. Biochem J 2004;379(Pt 3):533-540.
16. Falany CN, Comer KA, Dooley TP, Glatt H. Human dehydroepiandrosterone sulfotransferase. Purification, molecular cloning, and characterization. Ann NY Acad Sci 1995;774:59-72.
17. Meloche CA. The activity and expression of the sulfotransferase 2B1 isoforms in human prostate, placenta, breast and skin. [Ph. D. Dessertation]. Birmingham: University of Alabama at Birmingham 2003.
18. Konig JJ, Kamst E, Hagemeijer A, Romijn JC, Horoszewicz J, Schroder FH. Cytogenetic characterization of several androgen responsive and unresponsive sublines of the human prostatic carcinoma cell line LNCaP. Urol Res 1989;17(2):79-86.
19. Falany CN. Human cytosolic sulfotransferases: Properties, physiological functions, and toxicology. In: Methods in pharmacology and toxicology. Drug metabolism and transport: Molecular methods and mechanism. 2005. editors. Lash LH, Humana Press Totowa, NJ: pp. 341-378.
20. Falany CN, Wheeler J, Oh TS, Falany J. Steroid sulfation by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol 1994;48:369-375.
21. Rajagopal S, Navone NM, Troncoso P, Fritsche HA, Chakrabarty S. Modulation of cellular proliferation and production of prostate-specific antigen and matrix adhesion molecules in human prostate carcinoma cells by polypeptide growth factors: Comparative analyses of MDA PCa2a with established cell lines. Int J Oncol 1998;12(3):589-595.
22. Geller J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Semin Oncol 1985;12 (1 Suppl 1):28-35.
23. Labrie F, Luu-The V, Labrie C, Simard J. DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Front Neuroendocrinol 2001; 22(3):185-212.
24. Labrie F, Dupont A, Simard J, Luu-The V, Belanger A. Intracrinology: The basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur Urol 1993;24 (Suppl 2):94-105.
25. Falany JL, Azziz R, Falany CN. Identification and characterization of cytosolic sulfotransferases in normal human endometrium. Chem Biol Interact 1998;109(1-3):329-339.
26. Falany JL, Falany CN. Regulation of estrogen activity by sulfation in human MCF-7 breast cancer cells. Oncol Res 1997; 9(11-12):589-596.
27. Her C, Wood TC, Eichler EE, Mohrenweiser HW, Ramagli LS, Siciliano MJ, Weinshilboum RM. Human hydroxysteroid sulfotransferase SULT2 B1: Two enzymes encoded by a single chromosome 19 gene. Genomics 1998;53(3):284-295.
28. Geese WJ, Raftogianis RB. Biochemical characterization and tissue distribution of human SULT2 B1. Biochem Biophys Res Commun 2001;288(1):280-289.
29. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64(2):765-771.
30. Chen F, Knecht K, Birzin E, Fisher J, Wilkinson H, Mojena M, Moreno CT, Schmidt A, Harada S, Freedman LP, Reszka AA. Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology 2005;146(11):4568-4576.
31. Mo Q, Lu SF, Hu S, Simon NG. DHEA and DHEA sulfate differentially regulate neural androgen receptor and its transcriptional activity. Brain Res Mol Brain Res 2004;126(2):165-172.
32. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992;41(3-8):665-669.
33. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11(4):450-459.
34. Grigoryev DN, Long BJ, Njar VC, Brodie AH. Pregnenolone stimulates LNCaP prostate cell growth via the mutated androgen receptor. J Steroid Biochem Mol Biol 2000;75(1):1-10.
35. Harkonen PL, Makela SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol 2004;92(4):297-305.
36. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res 2000;60(12):3175-3182.
37. Linja MJ, Savinainen KJ, Tammela TL, Isola JJ, Visakorpi T. Expression of ERalpha and ERbeta in prostate cancer. Prostate 2003;55(3):180-186.
38. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001;159(1):79-92.
39. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson JA, Sutherland RL. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 2001;61(14):5331-5335.
40. Ji Q, Liu PI, Elshimali Y, Stolz A. Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR. Mol Cell Endocrinol 2005; 229(1-2):103-110.
41. Zeng Y, Yokohira M, Saoo K, Takeuchi H, Chen Y, Yamakawa K, Matsuda Y, Kakehi Y, Imaida K. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor. Carcinogenesis 2005;26(6):1109-1116.
42. Horton J, Rosenbaum C, Cummings FJ. Tamoxifen in advanced prostate cancer: An ECOG pilot study. Prostate 1988;12(2):173-177.
43. Bosland MC. The role of estrogens in prostate carcinogenesis: A rationale for chemoprevention. Rev Urol 2005;7 (Suppl 3):S4-S10.
44. Usui T. Pharmaceutical prospects of phytoestrogens. Endocr J 2006;53(1):7-20.
45. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 1998;95(26):15677- 15682.
46. Kotov A, Falany JL, Wang J, Falany CN. Regulation of estrogen activity by sulfation in human Ishikawa endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol 1999;68(34): 137-144.
47. Weihua Z, Warner M, Gustafsson JA. Estrogen receptor beta in the prostate. Mol Cell Endocrinol 2002;193(12):1-5.
48. Arnold JT, Le H, McFann KK, Blackman MR. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab 2005; 288(3):E573-E584.
49. Guerini V, Sau D, Scaccianoce E, Rusmini P, Ciana P, Maggi A, Martini PG, Katzenellenbogen BS, Martini L, Motta M, Poletti A. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res 2005;65(12):5445-5453.
50. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139(10):4252- 4263.
51. He D, Frost AR, Falany CN. Functional role of sulfotransferase 2B1b in human prostate cancer. In: 97th American Association for Cancer Research Annual Meeting, Apr 1-5, 2006, Washington, DC, pp 5342, AACR, Philadelphia.
52. Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba MM. PROMO: Detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 2002; 18(2):333-334.
53. Farre D, Roset R, Huerta M, Adsuara JE, Rosello L, Alba MM, Messeguer X. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res 2003;31(13):3651-3653.
54. Jiang YJ, Kim P, Elias PM, Feingold KR. LXR and, PPAR activators stimulate cholesterol sulfotransferase type 2 isoform lb in human keratinocytes. J Lipid Res 2005;46(12):2657-2666.
55. Lee YC, Higashi Y, Luu C, Shimizu C, Strott CA. Sp1 elements in SULT2B1b promoter and 5′-untranslated region of mRNA: Sp1/Sp2 induction and augmentation by histone deacetylase inhibition. FEBS Lett 2005;579(17):3639- 3645.
56. Baird DT, Uno A, Melby JC. Adrenal secretion of androgens and oestrogens. J Endocrinol 1969;45(1):135-136.
57. Comer KA, Falany CN. Immunological characterization of dehydroepiandrosterone sulfotransferase from human liver and adrenal. Mol Pharmacol 1992;41(4):645-651.
58. Parker CR Jr, Stankovic AK, Falany CN, Faye-Petersen O, Grizzle WE. Immunocytochemical analyses of dehydroepiandrosterone sulfotransferase in cultured human fetal adrenal cells. J Clin Endocrinol Metab 1995;80(3):1027- 1031.